



NDA 20-402/S-024

Wyeth Consumer Healthcare
Attention: Suzanne Brabant
Associate Director, Regulatory Affairs
Five Giralda Farms
Madison, NJ 07940

Dear Ms. Brabant:

Please refer to your supplemental new drug application dated December 21, 2007, received December 21, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Advil Liquigels (200 mg ibuprofen capsules) and Advil Migraine (200 mg ibuprofen capsules).

This supplemental new drug application provides for the addition of the warning statement "Ask a doctor before use if you have [bullet] asthma" to the Drug Facts label.

We have completed our review of this supplemental new drug application. This application is approved for the Advil Liquigels 2-, 4-, 20-, 80-count (representative of the 40-, 80-, 135-, and 180-count), and 240-count package sizes, and the Advil Migraine 20-, and 40-count (representative of the 40- and 80-count) package sizes), effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (Advil Liquigels 2-count front and back pouch labels, 2-count pouch dispenser (50 x 2-count pouches), 4-count blister carton card, 20-count carton label, 80-count (representative of the 40-, 80-, 135-, and 180-count) carton label, 240-count immediate container label, Advil Migraine 20-count carton label, and Advil Migraine 40-count (representative of the 40- and 80-count) carton label submitted December 21, 2007), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit an electronic version of the FPL for all represented stock keeping units according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-402/S-024.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Neel Patel, Regulatory Project Manager, at (301) 796-0970.

Sincerely,

{See appended electronic signature page}

Andrea Leonard-Segal, MD
Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Andrea Segal
6/11/2008 03:38:09 PM